H. Takeuchi

发表

Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.

M. Chakravarty, Y. Iwata, J. Chung, 2017, Journal of Alzheimer's disease : JAD.

The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report.

M. Chakravarty, A. Strafella, Y. Iwata, 2017, Journal of Alzheimer's disease : JAD.

Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment.

M. Chakravarty, B. Mulsant, Y. Iwata, 2015, Journal of Alzheimer's disease : JAD.

Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study

R. Bies, Masaru Mimura, H. Uchida, 2021, Therapeutic advances in psychopharmacology.

Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year

M. Mimura, H. Uchida, H. Takeuchi, 2015, Psychiatry Research.

A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder

G. Remington, H. Takeuchi, 2013, Psychopharmacology.

The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data

Y. Iwata, J. Chung, P. Gerretsen, 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

What does schizophrenia teach us about antipsychotics?

G. Remington, Jimmy Lee, G. Foussias, 2015, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls.

G. Remington, Jimmy Lee, H. Takeuchi, 2014, Journal of clinical psychopharmacology.

Relationship between polydipsia and antipsychotics: A systematic review of clinical studies and case reports

Masaru Mimura, H. Uchida, H. Takeuchi, 2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration.

Seung-hyun Kim, H. Uchida, Yohan Lee, 2021, The Journal of clinical psychiatry.

Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms

G. Remington, S. Farooq, Jimmy Lee, 2015, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Risk of neutropenia in a clozapine-treated elderly population

G. Remington, M. Guenette, G. Foussias, 2013, Schizophrenia Research.

Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis

Masaru Mimura, H. Uchida, K. Sawada, 2021, Pharmacopsychiatry.

Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia

H. Takeuchi, Kazunari Yoshida, 2021, Behavioural Brain Research.

Prescription patterns of psychotropics in patients receiving synthetic glucocorticoids

M. Mimura, H. Uchida, K. Yoshimura, 2020, Acta psychiatrica Scandinavica.

Combination Therapy of Long-Acting Injectable Second-Generation Antipsychotics and Oral Antipsychotics

H. Takeuchi, F. Misawa, Y. Fujii, 2021, Journal of clinical psychopharmacology.

Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan

H. Takeuchi, F. Misawa, Y. Fujii, 2021, Schizophrenia Research.

Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly? Analysis Based on a Spontaneous Reporting System Database in Japan.

H. Takeuchi, F. Misawa, Y. Fujii, 2021, Journal of clinical psychopharmacology.

Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia

G. Remington, Masaru Mimura, Koichiro Watanabe, 2014, Psychiatry Research.

Drug Combinations for Mood Disorders and Physical Comorbidities That Need Attention: A Cross-Sectional National Database Survey.

Masaru Mimura, H. Uchida, H. Takeuchi, 2022, Pharmacopsychiatry.

Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first‐episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms

Y. Takekita, H. Hori, H. Takeuchi, 2021, Human psychopharmacology.

Representativeness of clinical PET study participants with schizophrenia: A systematic review.

M. Mimura, H. Uchida, H. Takeuchi, 2017, Journal of psychiatric research.

Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms

M. Mimura, Koichiro Watanabe, H. Uchida, 2012, Schizophrenia Research.

Guidelines for Discontinuation of Antipsychotics in Patients Who Recover From First-Episode Schizophrenia Spectrum Disorders: Derived From the Aggregated Opinions of Asian Network of Early Psychosis Experts and Literature Review

E. Chen, C. Hui, H. Takeuchi, 2022, The international journal of neuropsychopharmacology.

Incidence of deep vein thrombosis in restrained psychiatric patients.

M. Mimura, Koichiro Watanabe, H. Uchida, 2014, Psychosomatics.

Trazodone and Mianserin for Delirium

Masaru Mimura, D. Fujisawa, H. Uchida, 2022, Journal of clinical psychopharmacology.

Pathophysiology, prognosis and treatment of tardive dyskinesia

H. Takeuchi, Yasuhiro Mori, Y. Tsutsumi, 2022, Therapeutic advances in psychopharmacology.

Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial.

G. Remington, Jimmy Lee, G. Foussias, 2017, The Journal of clinical psychiatry.

A Randomized, Open-Label Comparison of 2 Switching Strategies to Aripiprazole Treatment in Patients With Schizophrenia: Add-On, Wait, and Tapering of Previous Antipsychotics Versus Add-On and Simultaneous Tapering

H. Kashima, S. Nakajima, Koichiro Watanabe, 2008, Journal of clinical psychopharmacology.

Measuring motivation in people with schizophrenia

G. Remington, G. Foussias, G. Fervaha*, 2015, Schizophrenia Research.

Antipsychotic Medications: Enhancing Use to Improve Outcomes.

G. Remington, J. Kane, S. Leucht, 2021, Schizophrenia bulletin.

Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms

Masaru Mimura, H. Uchida, H. Takeuchi, 2019, Schizophrenia Research.

Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review.

M. Mimura, H. Uchida, K. Takahata, 2020, The Journal of clinical psychiatry.

Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data.

G. Remington, R. Bies, H. Uchida, 2014, The Journal of clinical psychiatry.

Clinical Outcomes after Clozapine Discontinuation in Patients with Schizophrenia: A Systematic Review.

Masaru Mimura, H. Uchida, H. Takeuchi, 2022, Pharmacopsychiatry.

Longitudinal changes in clozapine dose in patients with treatment-resistant schizophrenia: a 5-year retrospective cohort study

S. Nakajima, H. Takeuchi, Ryuhei So, 2022, International clinical psychopharmacology.

The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study

G. Remington, R. Bies, Jimmy Lee, 2015, Journal of clinical psychopharmacology.

How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review.

H. Kashima, S. Nakajima, Koichiro Watanabe, 2011, Journal of psychiatric research.

Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study

B. Pollock, A. Graff-Guerrero, F. Caravaggio, 2015, Pharmacopsychiatry.

Analysis of antipsychotic dose reduction.

H. Uchida, D. Mamo, H. Takeuchi, 2010, The American journal of psychiatry.

Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis

C. Eap, M. Roy, P. Homan, 2022, European Archives of Psychiatry and Clinical Neuroscience.

Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan

H. Takeuchi, Yasuhiro Mori, Y. Tsutsumi, 2022, Therapeutic advances in psychopharmacology.

A review on schizophrenia and relapse—a quest for user‐friendly psychopharmacotherapy

M. Mimura, H. Uchida, J. Hirano, 2014, Human psychopharmacology.

Impacts of Switching Antidepressants After Successful Electroconvulsive Therapy on the Maintenance of Clinical Remission in Patients With Treatment-Resistant Depression: A Chart Review

H. Kashima, Rei Akaishi, A. Nakagawa, 2009, The journal of ECT.

Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials

M. Mimura, H. Uchida, H. Takeuchi, 2019, Neuropsychopharmacology.

Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia

G. Remington, R. Zipursky, G. Foussias, 2018, Neuropsychopharmacology.

Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan.

B. Mulsant, H. Kashima, Koichiro Watanabe, 2009, Journal of anxiety disorders.

Placebo versus no treatment for people with schizophrenia

S. Leucht, O. Agid, H. Takeuchi, 2023, Cochrane Database of Systematic Reviews.

Effectiveness of mindfulness-based interventions for people with dementia and mild cognitive impairment: A meta-analysis and implications for future research

M. Sado, H. Takeuchi, M. Nagaoka, 2021, PloS one.

Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis

G. Remington, M. Chakravarty, Y. Iwata, 2017, Schizophrenia bulletin.

Dental conditions in inpatients with schizophrenia: A large-scale multi-site survey

M. Mimura, H. Shimanuki, S. Nakajima, 2012, BMC oral health.

Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis

G. Remington, H. Takeuchi, F. Misawa, 2020, CNS Drugs.

Pharmacological interventions for prevention of weight gain in people with schizophrenia

G. Remington, V. Taylor, G. Faulkner, 2019, Cochrane Database of Systematic Reviews.

The potential role of dopamine D3 receptor neurotransmission in cognition

Tiffany E. Chow, B. Pollock, B. Mulsant, 2013, European Neuropsychopharmacology.

Dopamine D2 Receptor Occupancy and Clinical Effects: A Systematic Review and Pooled Analysis

A. Graff-Guerrero, Koichiro Watanabe, H. Uchida, 2011, Journal of clinical psychopharmacology.

Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology.

M. Mimura, R. Bies, H. Uchida, 2019, Journal of psychiatric research.

Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.

G. Remington, M. Mimura, R. Bies, 2013, Schizophrenia bulletin.

Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review

G. Remington, H. Uchida, H. Takeuchi, 2015, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Treating Negative Symptoms in Schizophrenia: an Update

G. Remington, Jimmy Lee, G. Foussias, 2016, Current Treatment Options in Psychiatry.

Factor Structure of the Targeted Inventory on Problems in Schizophrenia

M. Mimura, S. Nakajima, Koichiro Watanabe, 2013, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

Differential associations of dopamine synthesis capacity with the dopamine transporter and D2 receptor availability as assessed by PET in the living human brain

Harumasa Takano, Yasuyuki Kimura, Keisuke Takahata, 2020, NeuroImage.

Relationship between clinical improvement and functional gains with clozapine in schizophrenia

G. Remington, Jimmy Lee, G. Fervaha*, 2014, European Neuropsychopharmacology.

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.

D. Kelly, E. Seifritz, Abraham Weizman, 2021, Pharmacopsychiatry.

Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm

H. Takeuchi, Chen-Chung Liu, 2019, CNS Drugs.

Neurocognitive impairment in the deficit subtype of schizophrenia

G. Remington, G. Foussias, G. Fervaha*, 2016, European Archives of Psychiatry and Clinical Neuroscience.

Neuroimaging findings in treatment-resistant schizophrenia: A systematic review Lack of neuroimaging correlates of treatment-resistant schizophrenia

G. Remington, Y. Iwata, J. Chung, 2015, Schizophrenia Research.

Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One‐year follow‐up study

H. Kashima, Koichiro Watanabe, H. Uchida, 2010, Psychiatry and clinical neurosciences.

Development of diagnostic criteria and severity scale for polydipsia: A systematic literature review and well-experienced clinicians’ consensus

Masaru Mimura, H. Uchida, H. Takeuchi, 2021, Psychiatry Research.

Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia

G. Remington, Christina L. M. Hill, R. Kern, 2015, Schizophrenia Research.

Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia

G. Remington, K. Zakzanis, A. Graff-Guerrero, 2015, Schizophrenia Research.

Novel rating scales for schizophrenia — Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz)

H. Kashima, S. Nakajima, Koichiro Watanabe, 2008, Schizophrenia Research.

Augmentation of atypical antipsychotics with valproic acid. An open‐label study for most difficult patients with schizophrenia

H. Kashima, S. Nakajima, Koichiro Watanabe, 2009, Human psychopharmacology.

Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study

G. Remington, G. Foussias, G. Fervaha*, 2014, European Neuropsychopharmacology.

Olanzapine Reduction From High Dose to Standard Dose

H. Takeuchi, F. Misawa, Y. Fujii, 2021, Journal of clinical psychopharmacology.

Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?

Koichiro Watanabe, H. Takeuchi, Takefumi Suzuki, 2010, The Journal of clinical psychiatry.

Relationship Between Symptomatic Improvement and Overall Illness Severity in Patients With Schizophrenia

G. Remington, Jimmy Lee, G. Foussias, 2015, Journal of clinical psychopharmacology.

Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study

G. Remington, Eric E Brown, Y. Iwata, 2019, European Archives of Psychiatry and Clinical Neuroscience.

Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial

M. Mimura, H. Kashima, S. Nakajima, 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Language Barriers and Access to Psychiatric Care: A Systematic Review.

H. Uchida, H. Takeuchi, Takefumi Suzuki, 2015, Psychiatric services.

Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic Drugs: A Systematic Review and Pooled Analysis

A. Graff-Guerrero, Koichiro Watanabe, H. Uchida, 2011, Journal of clinical psychopharmacology.

Risk of withdrawal of consent for treatment with long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled trials

H. Takeuchi, F. Misawa, Y. Fujii, 2020, Schizophrenia Research.

Effectiveness of brexpiprazole in the treatment in a patient with Huntington's disease

M. Mimura, H. Takeuchi, Y. Mimura, 2020, Psychiatry and clinical neurosciences.

Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms

Masaru Mimura, H. Uchida, H. Takeuchi, 2021, Schizophrenia Research.

Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis.

G. Remington, S. Leucht, O. Agid, 2020, Schizophrenia bulletin.

Relationship between regional gray matter volumes and dopamine D2 receptor and transporter in living human brains

T. Suhara, Hiroshi Ito, M. Higuchi, 2021, Human brain mapping.

Antipsychotics and Amotivation

P. Fletcher, G. Remington, Jimmy Lee, 2015, Neuropsychopharmacology.

Incidence of Antipsychotic-Associated Side Effects: Impact of Clinician Versus Patient Ratings and Change Versus Absolute Scores

G. Remington, G. Fervaha*, H. Takeuchi, 2016, Journal of clinical psychopharmacology.

Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open‐label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone

H. Kashima, S. Nakajima, Koichiro Watanabe, 2008, Human psychopharmacology.

Life satisfaction and happiness among young adults with schizophrenia

G. Remington, G. Foussias, G. Fervaha*, 2016, Psychiatry Research.

Clinical and Functional Outcomes in People With Schizophrenia With a High Sense of Well-Being

G. Remington, Jimmy Lee, G. Foussias, 2015, The Journal of nervous and mental disease.

Clinical determinants of life satisfaction in chronic schizophrenia: Data from the CATIE study

G. Remington, G. Foussias, G. Fervaha*, 2013, Schizophrenia Research.

Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data

B. Pollock, G. Remington, R. Bies, 2013, Schizophrenia Research.

Longitudinal changes in antipsychotic dose in patients treated with long-acting injectable second-generation antipsychotics.

H. Takeuchi, Ryuhei So, F. Misawa, 2021, International clinical psychopharmacology.

Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia

M. Mimura, H. Uchida, H. Takeuchi, 2015, Psychiatry Research.

Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan.

H. Takeuchi, F. Misawa, Y. Fujii, 2022, Journal of Clinical Psychiatry.

Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials.

G. Remington, O. Agid, H. Takeuchi, 2018, The Journal of clinical psychiatry.

Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis

G. Remington, H. Uchida, H. Takeuchi, 2017, Schizophrenia bulletin.

Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan

B. Mulsant, H. Kashima, S. Nakajima, 2009, Psychiatry and clinical neurosciences.

One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis.

G. Remington, G. Fervaha*, O. Agid, 2017, The British journal of psychiatry : the journal of mental science.

The importance of early and proactive use of long-acting injectable antipsychotics in the management of schizophrenia.

H. Takeuchi, 2023, International clinical psychopharmacology.

Effects of Discontinuation of Drugs Used for Augmentation Therapy on Treatment Outcomes in Depression: A Systematic Review and Meta-analysis

M. Mimura, H. Uchida, H. Takeuchi, 2020, Pharmacopsychiatry.

Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome

G. Remington, G. Foussias, G. Fervaha*, 2018, Early intervention in psychiatry.

Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.

G. Remington, M. Mimura, R. Bies, 2014, The Journal of clinical psychiatry.

Insight into illness and its relationship to illness severity, cognition and estimated antipsychotic dopamine receptor occupancy in schizophrenia: An antipsychotic dose reduction study

P. Gerretsen, A. Graff-Guerrero, H. Uchida, 2017, Psychiatry Research.

Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition

C. Correll, E. Fernandez-Egea, C. Eap, 2023, Schizophrenia Research.

A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder

G. Remington, H. Takeuchi, 2013, Psychopharmacology.

Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study.

H. Kashima, Koichiro Watanabe, H. Uchida, 2009, Journal of clinical psychopharmacology.

Predictors of response to pharmacotherapy in children and adolescents with psychiatric disorders: A combined post hoc analysis of four clinical trial data

Masaru Mimura, H. Uchida, H. Takeuchi, 2022, Neuropsychopharmacology reports.

Combined Treatment With Sulpiride and Paroxetine for Accelerated Response in Patients With Major Depressive Disorder

H. Kashima, Koichiro Watanabe, H. Uchida, 2005, Journal of clinical psychopharmacology.

Priapism and Second‐Generation Antipsychotics: Disproportionality Analysis of a Spontaneous Reporting System Database in Japan

H. Takeuchi, F. Misawa, 2022, Psychiatry and clinical neurosciences.

Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

T. Arenovich, H. Uchida, D. Mamo, 2011, Schizophrenia bulletin.

Adherence to clozapine vs. other antipsychotics in schizophrenia

G. Remington, O. Agid, H. Takeuchi, 2020, Acta psychiatrica Scandinavica.

Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis

T. Kishimoto, Kentaro Matsui, Y. Takekita, 2019, Schizophrenia Research.

The evolution of antipsychotic switch and polypharmacy in natural practice — A longitudinal perspective

S. Kapur, S. Nakajima, Koichiro Watanabe, 2011, Schizophrenia Research.

Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia

H. Kashima, Koichiro Watanabe, H. Uchida, 2005, Psychopharmacology.

The neurobiology of relapse in schizophrenia

G. Remington, G. Foussias, G. Fervaha*, 2014, Schizophrenia Research.

The promise and pitfalls of antipsychotic co-initiation in schizophrenia.

H. Takeuchi, 2022, The lancet. Psychiatry.

Association between subjective distress and symptom domains in patients with treatment-resistant schizophrenia receiving clozapine

Masaru Mimura, H. Uchida, H. Takeuchi, 2022, Schizophrenia Research.

What symptom domains are associated with patient distress in schizophrenia?

G. Remington, Jimmy Lee, G. Fervaha*, 2016, Schizophrenia Research.

An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia.

H. Kashima, S. Nakajima, Koichiro Watanabe, 2007, Journal of clinical psychopharmacology.

Patient’s trust in their psychiatrist: a cross-sectional survey

H. Kashima, S. Nakajima, Koichiro Watanabe, 2011, European Archives of Psychiatry and Clinical Neuroscience.

Rapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis

G. Remington, O. Agid, H. Takeuchi, 2017, Schizophrenia Research.

Factors associated with drug attitude in patients with schizophrenia spectrum disorders

G. Remington, H. Takeuchi, Reza Hamidian, 2017, Schizophrenia Research.

Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratings

G. Remington, G. Fervaha*, H. Takeuchi, 2016, Psychiatry Research.

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?—A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting

H. Kashima, Koichiro Watanabe, H. Uchida, 2007, Psychopharmacology.

Appendicitis Associated With Clozapine

H. Takeuchi, F. Misawa, Y. Fujii, 2023, Journal of Clinical Psychopharmacology.

H. Takeuchi, F. Misawa, Y. Fujii, 2019, The Australian and New Zealand journal of psychiatry.

Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis

G. Remington, O. Agid, H. Takeuchi, 2017, Schizophrenia Research.

Positive Symptoms Are Associated With Clinicians’ Global Impression in Treatment-Resistant Schizophrenia

G. Remington, Jimmy Lee, G. Fervaha*, 2015, Journal of clinical psychopharmacology.

Melancholic and reactive depression: a reappraisal of old categories

M. Mimura, Koichiro Watanabe, H. Uchida, 2013, BMC Psychiatry.

Determinants of patient-rated and clinician-rated illness severity in schizophrenia.

G. Remington, Jimmy Lee, G. Foussias, 2014, The Journal of clinical psychiatry.

Using poverty of speech as a case study to explore the overlap between negative symptoms and cognitive dysfunction

G. Remington, G. Foussias, G. Fervaha*, 2016, Schizophrenia Research.

A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD).

G. Remington, Jimmy Lee, G. Fervaha*, 2016, Journal of psychiatric research.

Antipsychotic nonadherence measured by electronic adherence monitoring in stabilized chronic schizophrenia: Clinical implications

G. Remington, O. Agid, H. Takeuchi, 2021, Schizophrenia Research.

Does short‐term antipsychotic discontinuation of up to 3 weeks worsen symptoms in acute schizophrenia? A pooled analysis of placebo washout data

H. Takeuchi, K. Watabe, 2023, Psychiatry and clinical neurosciences.

Clinical outcomes after clozapine discontinuation in responders versus nonresponders: a retrospective chart review

H. Takeuchi, F. Misawa, Y. Fujii, 2021, International clinical psychopharmacology.

Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data

G. Remington, B. Mulsant, Y. Iwata, 2015, Schizophrenia Research.

Pharmacological interventions for prevention of weight gain in people with schizophrenia.

G. Remington, V. Taylor, G. Faulkner, 2022, The Cochrane database of systematic reviews.

Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia

G. Remington, G. Fervaha*, H. Takeuchi, 2015, Journal of clinical psychopharmacology.

Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia

Kenji F. Tanaka, Masahiko Watanabe, Sho Yagishita, 2023, bioRxiv.

Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review

G. Remington, G. Fervaha*, H. Takeuchi, 2017, Journal of clinical psychopharmacology.

Association of protein distribution and gene expression revealed by positron emission tomography and postmortem gene expression in the dopaminergic system of the human brain.

K. Matsuoka, Masaru Mimura, K. Tagai, 2023, European journal of nuclear medicine and molecular imaging.

Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls.

G. Remington, Jimmy Lee, H. Takeuchi, 2014, Journal of clinical psychopharmacology.

Clozapine dosing patterns and clinical outcomes in patients with treatment resistant schizophrenia

W. Honer, E. Chen, W. Chang, 2023, European Neuropsychopharmacology.

Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis

G. Remington, H. Takeuchi, 2020, Journal of psychopharmacology.

Relationship Between Symptomatic Improvement and Overall Illness Severity in Patients With Schizophrenia

G. Remington, Jimmy Lee, G. Foussias, 2015, Journal of clinical psychopharmacology.

Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia

G. Remington, Jimmy Lee, G. Fervaha*, 2015, European Neuropsychopharmacology.

Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia

G. Remington, K. Zakzanis, A. Graff-Guerrero, 2015, Schizophrenia Research.

Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data

G. Remington, B. Mulsant, Y. Iwata, 2015, Schizophrenia Research.

Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study

R. Bies, A. Graff-Guerrero, F. Caravaggio, 2015, Pharmacopsychiatry.

Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia

T. Kishimoto, Y. Takaesu, Kentaro Matsui, 2023, Neuropsychopharmacology reports.

Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis

S. Leucht, H. Takeuchi, S. Siafis, 2023, Molecular Psychiatry.

Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan.

B. Mulsant, H. Kashima, Koichiro Watanabe, 2009, Journal of anxiety disorders.

Dopamine D2 Receptor Occupancy and Clinical Effects: A Systematic Review and Pooled Analysis

A. Graff-Guerrero, Koichiro Watanabe, H. Uchida, 2011, Journal of clinical psychopharmacology.

Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia.

G. Remington, M. Mimura, Koichiro Watanabe, 2014, Journal of clinical psychopharmacology.